IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stok Raporu

Piyasa değeri: US$2.6b

IDEAYA Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

IDEAYA Biosciences CEO'su Yujiro Hata, Jun2015 tarihinde atandı, in görev süresi 10.92 yıldır. in toplam yıllık tazminatı $ 9.51M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.4% maaş ve 92.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.79% ine doğrudan sahiptir ve bu hisseler $ 20.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 7.5 yıldır.

Anahtar bilgiler

Yujiro Hata

İcra Kurulu Başkanı

US$9.5m

Toplam tazminat

CEO maaş yüzdesi7.36%
CEO görev süresi10.9yrs
CEO sahipliği0.8%
Yönetim ortalama görev süresi2.4yrs
Yönetim Kurulu ortalama görev süresi7.5yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • May 08

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders are probably feeling a little disappointed, since its shares fell...
Analiz Makalesi • May 07

Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates

Market forces rained on the parade of IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders today, when the analysts...
Seeking Alpha • Apr 08

Ideaya Biosciences: Key Pivotal Data Imminent

Summary Ideaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melanoma candidate. IDYA maintains a strong cash runway of 3–4 years, supporting a robust and expanding pipeline targeting multiple high-value oncology indications. Darovasertib has shown promising efficacy as both monotherapy and in combination, with phase 3 data expected imminently and potential for FDA approval. Despite aggressive valuation and rising cash burn, I maintain a Buy rating, confident in IDYA's strategic positioning and clinical potential. Read the full article on Seeking Alpha
Analiz Makalesi • Jul 28

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 16

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Summary IDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutations, showing promising clinical activity. With over $1 billion in cash and other investments, IDYA has 4–5 years of operational liquidity. Strength: Strong liquidity. Risk: Heavy reliance on key data catalysts for future success. Read the full article on Seeking Alpha
Analiz Makalesi • Apr 13

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 10

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Summary Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uveal melanoma; mPFS data expected end of 2025. Darovasertib is also being evaluated in another phase 2 study as a monotherapy targeting neoadjuvant uveal melanoma patients, with data expected in 2025. The global uveal melanoma treatment market is projected to reach $3.22 billion by the end of 2034. IDYA is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028, reducing near-term dilution risk. Read the full article on Seeking Alpha
Analiz Makalesi • Jan 03

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 04

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Summary Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile. With a market cap of $2.37bn and a cash runway into 2028, IDYA is financially well-positioned, despite the inherent risks of late-stage studies. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Summary IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates in MTAP-deleted solid tumors. Strategic partnerships with Pfizer, Amgen, Gilead, and GSK validate IDEAYA's technology and offer substantial potential milestone payments. IDE397 shows a 94% disease control rate in Phase 2 trials for MTAP-deleted tumors, with favorable safety and efficacy profiles, positioning it as a potential first-in-class treatment. IDYA has a robust cash runway and reasonable valuation, which is why I rate it a "buy" for long-term biotech investors. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Summary Ideaya Biosciences is a cancer-focused biotech with promising pipeline candidates darovasertib and IDE397 targeting uveal melanoma and MTAP-deleted cancers. Darovasertib has shown strong results in phase 2 trials for uveal melanoma, while IDE397 demonstrated positive phase 2 data for MTAP-deleted NSCLC and urothelial cancer. With a solid financial position and potential for accelerated approvals, IDYA presents a compelling investment opportunity, although the current valuation may be high. Read the full article on Seeking Alpha
Seeking Alpha • Jun 18

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and has a fortress balance sheet. An updated analysis around Ideaya Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 22

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 16

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Summary IDEAYA Biosciences' stock has increased by 57% since September, outperforming the S&P 500. PRMT5 inhibitors have gained attention in the biotech industry, with Bristol Myers paying $5.8 billion, in part, for Mirati's PRMT5 medication. IDEAYA's second lead drug, IDE397, is a PRMT5 inhibitor being studied in combination with an Amgen drug, with worldwide commercial rights retained by IDEAYA. Given the company's strategic positioning and the high unmet medical need in its target indications, IDEAYA appears to be a promising investment with significant upside potential. Read the full article on Seeking Alpha

CEO Tazminat Analizi

Yujiro Hata'un ücretlendirmesi IDEAYA Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$140m

Dec 31 2025US$10mUS$700k

-US$114m

Sep 30 2025n/an/a

-US$161m

Jun 30 2025n/an/a

-US$332m

Mar 31 2025n/an/a

-US$307m

Dec 31 2024US$17mUS$646k

-US$274m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$154m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$6mUS$598k

-US$113m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$570k

-US$59m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$544k

-US$50m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$2mUS$510k

-US$34m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$457k

-US$42m

Tazminat ve Piyasa: Yujiro 'nin toplam tazminatı ($USD 9.51M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 7.00M ).

Tazminat ve Kazançlar: Yujiro 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Yujiro Hata (51 yo)

10.9yrs
Görev süresi
US$9,512,640
Tazminat

Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Yujiro Hata
Founder10.9yrsUS$9.51m0.79%
$ 20.3m
Joshua Bleharski
Chief Financial Officer1yrUS$4.15mVeri yok
Andres Briseno
Chief Accounting Officer2.8yrsUS$1.65m0.030%
$ 776.7k
Michael White
Chief Scientific Officer4.6yrsUS$3.32mVeri yok
Douglas Snyder
Chief Legal Officer1.7yrsUS$1.13m0.0024%
$ 61.1k
Darrin Beaupre
Chief Medical Officer3.5yrsUS$3.33mVeri yok
Paul Barsanti
Chief Technology Officer3.3yrsVeri yokVeri yok
Francine Zelaya
Senior VP & Head of Human Resources1.9yrsVeri yokVeri yok
Mick O'Quigley
Senior Vice President of Medical Writing & Project Management4.2yrsVeri yokVeri yok
Daniel Simon
Chief Business Officer1.8yrsVeri yokVeri yok
Stuart Dorman
Chief Commercial Officer1.4yrsUS$3.42mVeri yok
Jasgit Sachdev
Senior Vice President of Late Phase Clinical Development & Strategy1.3yrsVeri yokVeri yok
2.4yrs
Ortalama Görev Süresi
51yo
Ortalama Yaş

Deneyimli Yönetim: IDYA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Yujiro Hata
Founder10.9yrsUS$9.51m0.79%
$ 20.3m
Wendy Yarno
Independent Director6.4yrsUS$344.16kVeri yok
Jeffrey Stein
Independent Director10.6yrsUS$351.66k0.069%
$ 1.8m
Frank McCormick
Chair of Scientific Advisory Board7.3yrsVeri yokVeri yok
Scott William Morrison
Independent Director7.8yrsUS$351.66kVeri yok
Catherine Mackey
Independent Director4.1yrsUS$334.16kVeri yok
Trey Ideker
Member of Scientific Advisory Board10yrsVeri yokVeri yok
William Sellers
Member of Scientific Advisory Board7.3yrsVeri yokVeri yok
Elizabeth Swisher
Member of Scientific Advisory Board10yrsVeri yokVeri yok
Terry Rosen
Independent Chairman of the Board10.3yrsUS$379.16k0.0093%
$ 239.8k
Malcolm Hampton
Independent Director5.9yrsUS$331.66kVeri yok
Karlene Cimprich
Member of Scientific Advisory Board3.4yrsVeri yokVeri yok
7.5yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: IDYA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/27 10:19
Gün Sonu Hisse Fiyatı2026/05/27 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

IDEAYA Biosciences, Inc. 32 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Madhu KumarBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG